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ABSTRACT
The correlation between results obtained with the European Committee on Antibiotic Susceptibility
Testing (EUCAST) antifungal susceptibility testing procedure (document 7.1) and four commercial
systems was evaluated for a collection of 93 clinical isolates of Candida spp. Overall, agreement between
the EUCAST procedure and the Sensititre YeastOne and Etest methods was 75% and 90.4%,
respectively. The correlation indices (p < 0.01) between the EUCAST and commercial methods were 0.92
for Sensititre YeastOne, 0.89 for Etest, ) 0.90 for Neo-Sensitabs, and 0.95 for Fungitest. Amphotericin B
MICs obtained by Sensititre YeastOne were consistently higher than with the EUCAST method and,
although very major errors were not observed, 91% of MICs were misclassiﬁed. Amphotericin B- and
ﬂuconazole-resistant isolates were identiﬁed correctly with Sensititre YeastOne, Etest and Fungitest.
Neo-Sensitabs identiﬁed amphotericin B-resistant isolates, but misclassiﬁed > 5% of ﬂuconazole-
resistant isolates as susceptible. The commercial methods, particularly Etest and Fungitest, appeared to
be suitable alternatives to the EUCAST procedure for antifungal susceptibility testing of clinical isolates
of Candida.
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INTRODUCTION
The Antifungal Susceptibility Testing Subcom-
mittee of the European Committee on Antibiotic
Susceptibility Testing (AFST-EUCAST) has
developed a standard broth microdilution pro-
cedure for the determination of antifungal MICs
for fermentative species of yeasts [1]. This
standard is based on the NCCLS reference
procedure described in document M27-A2 [2],
but includes some modiﬁcations to allow for
automation of the method and to permit the
incubation period to be shortened from 48 to
24 h. A multicentre evaluation has demonstrated
that the EUCAST procedure for antifungal
susceptibility testing is a reproducible method,
with 94% agreement between laboratories [3]. In
addition, a two-laboratory study evaluated the
correlation between the NCCLS M27-A and
EUCAST microdilution procedures with a panel
of 109 bloodstream isolates of Candida spp.,
tested against amphotericin B, ﬂucytosine, ﬂuc-
onazole and itraconazole, and demonstrated an
overall agreement of 92% and a correlation
coefﬁcient of 0.90 (p < 0.01) [4]. However,
standard reference procedures are generally not
practical for use in routine clinical laboratories,
since they involve rather complex methods for
susceptibility testing. Many microbiologists prefer
to use other systems with advantages such as
ease of performance, economy or more rapid
results. Several techniques based on agar diffu-
sion or use of a colorimetric oxidation–reduction
indicator have been developed. Some of these
techniques are available commercially, and are
rapid and simple alternatives to the procedures
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developed by either the EUCAST or NCCLS
[5–8].
A signiﬁcant use of reference procedures is to
provide a standard from which other methods
can be developed and compared. Many studies
have analysed the correlation between the NCCLS
procedure and various commercially available
systems [5–24], including some suitable for sus-
ceptibility testing of Candida spp. However, only
one study [25] has compared the EUCAST pro-
cedure with commercial systems. Therefore, the
aim of the present study was to analyse results
obtained with the EUCAST procedure and four
commercially available systems for a collection of
clinical isolates of Candida spp.
MATERIALS AND METHODS
Fungi
A collection of 93 non-duplicate clinical isolates of Candida
spp. was tested. Most (n = 49) were obtained from blood
cultures, while the remainder were from deep-site specimens
(n = 18) or oropharyngeal exudates (n = 26). The isolates
were selected to represent broad in-vitro susceptibility
ranges. Each isolate was sent to the Centro Nacional de
Microbiologı´a, Madrid, Spain for identiﬁcation or antifungal
susceptibility testing. Isolates were identiﬁed by routine
microbiological techniques (Table 1) and were maintained at
)70C. Candida parapsilosis ATCC 22019 and Candida krusei
ATCC 6258 were used as quality control strains in each set
of experiments.
Reference susceptibility testing
Standard powders of amphotericin B, ﬂucytosine, ﬂuconazole,
itraconazole, voriconazole and ketoconazole were supplied by
Sigma Aldrich Quimica (Madrid, Spain), Pﬁzer (Madrid,
Spain) and Janssen (Madrid, Spain). MICs were determined
with the AFST-EUCAST reference procedure (document 7.1)
[1]. In brief, testing was performed with RPMI-1640 medium
supplemented with glucose 2% w ⁄v, an inoculum size of
105 CFU ⁄mL and ﬂat-bottom microdilution plates [26]. MIC
endpoints were determined spectrophotometrically after 24
and 48 h. For amphotericin B, the MIC endpoints were deﬁned
as the lowest drug concentration that resulted in a reduction in
growth of ‡ 90% compared with that of a drug-free control
well. For ﬂucytosine and azoles, the MIC endpoint was deﬁned
as a 50% reduction in optical density.
Commercial techniques
Four commercial methods were investigated: Sensititre
YeastOne panel (Trek Diagnostic Systems, East Grinstead,
UK); Etest strips (AB Biodisk, Solna, Sweden) on RPMI-
1640 ⁄glucose 2% w ⁄v agar; Fungitest panel (Bio-Rad, Madrid,
Spain); and the agar diffusion method with Neo-Sensitabs
(A ⁄ S Rosco, Taastrup, Denmark). Susceptibility testing, read-
ing and interpretations of the results were performed in
accordance with the manufacturers’ instructions. Susceptibility
testing was performed in triplicate on three separate days.
Data analysis
Both on-scale and off-scale results obtained by the EUCAST
reference procedure were included in the analysis. The low off-
scale MICs were left unchanged, and the high off-scale MICs
were converted to the next highest concentration. The repro-
ducibility of the results obtained with the EUCAST technique
and the commercial methods was evaluated by using distinct
statistical tests, depending on the commercial technique
investigated, as test results were expressed in different units
(i.e., Sensititre YeastOne and Etest results were expressed in
mg ⁄L; Fungitest results in susceptible, intermediate and
resistant categories; and Neo-Sensitabs results in inhibition
(cm) diameters).
The reproducibility between the EUCAST results and MICs
obtained by Sensititre YeastOne and Etest was calculated by
determining the percentage of agreement between MICs.
Agreement was deﬁned as a discrepancy in MICs of no more
than two doubling dilutions. Results obtained by Etest were
adjusted to the nearest doubling dilution, up or down, as
tested by the EUCAST method. In addition, the correlation
between results was evaluated by using the intra-class corre-
lation coefﬁcient (ICC), which was expressed to a maximum
value of 1 and with a 95% CI. In order to approximate a
normal distribution, the MICs were transformed to log2 values.
A p value of < 0.01 was considered to be statistically
signiﬁcant. The ICC is a reverse measurement of the variability
of the counting values and was calculated using the formula
ICC = (group mean square ) error mean square) ⁄ (group
mean square + error mean square); it thus has a maximum
value of 1 if there is a perfect correlation and a minimum value
of ) 1 if there is a complete absence of correlation. The ICC
evaluates the correlation between values offering statistical
Table 1. Results obtained with the EUCAST procedure for Candida isolates included in the study
Species
MIC values (mg ⁄L)
No. of isolates Amphotericin B Flucytosine Fluconazole Itraconazole Voriconazole Ketoconazole
C. albicans 21 0.03–2.0 0.12–128.0 0.12–128.0 0.01–16.0 0.01–16.0 0.01–4.0
C. tropicalis 21 0.03–8.0 0.06–1.0 0.12–128.0 0.01–16.0 0.01–16.0 0.01–8.0
C. parapsilosis 12 0.03–1.0 0.12–0.50 0.12–2.0 0.01–0.12 0.01–0.03 0.01–0.06
C. glabrata 10 0.06–0.25 0.12–0.25 2.0–64.0 0.25–0.50 0.03–0.50 0.06–2.0
C. krusei 10 0.03–0.25 2.0–16.0 32.0–128.0 0.06–0.25 0.25–1.0 0.25–1.0
C. lusitaniae 11 0.03–1.0 0.12–0.25 0.12–64.0 0.01–0.12 0.01–0.50 0.01–1.0
C. guilliermondii 8 0.03–1.0 0.12–1.0 2.0–64.0 0.12–2.0 0.06–2.0 0.03–2.0
Total 93 0.03–8.0 0.12–128.0 0.12–128.0 0.01–16.0 0.01–16.0 0.01–8.0
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signiﬁcance, since it takes into account the number of cases
and absolute value of the counting. The ICC is a scales analysis
and exhibits the highest statistical power for correlation
studies.
The reproducibility between the EUCAST and Neo-Sen-
sitabs results was calculated by a simple correlation coefﬁ-
cient (Pearson’s coefﬁcient, r). The ICC cannot be used for
correlating variables that are not expressed in the same
units. A p value of < 0.01 was considered to be statistically
signiﬁcant.
The analysis of concordance between the EUCAST and
Fungitest data was performed by the gamma ordinal probabi-
listic measure. This summarises, on a ) 1 to + 1 scale, the extent
to which higher categories (based on the data codes used) of
one variable are associated with higher categories of the
second variable. Data codes used with Fungitest results were
susceptible = 0, intermediate = 1, and resistant = 2.
Categorical agreement between the EUCAST data and the
results obtained by the commercially available techniques was
also evaluated. The EUCAST has not deﬁned interpretative
breakpoints, while the breakpoints proposed by the NCCLS
for ﬂucytosine, ﬂuconazole and itraconazole were not used,
since substantial discrepancies have been observed among
ﬂuconazole-resistant isolates as a result of the well-known
tendency for MICs to rise by one or two dilutions between
incubation for 24 and 48 h [27]. It should be noted that the
EUCAST document recommends MIC determination at 24 h,
while the NCCLS M27-A2 methodology recommends an
endpoint reading after incubation for 48 h. Isolates were
classiﬁed as susceptible, intermediate or resistant, based on
the wild-type distribution of MICs determined by the EUCAST
method, on preliminary studies of the in-vitro ⁄ in-vivo corre-
lation for strains causing oropharyngeal candidosis in AIDS
patients, and on pharmacokinetic ⁄pharmacodynamic biblio-
graphic data [28–34]. It should be emphasised that these
breakpoints are tentative and could be changed when the
AFST-EUCAST reports new susceptibility data. Tentative
interpretative breakpoints were: (1) amphotericin B, suscept-
ible £ 0.25 mg ⁄L, intermediate 0.50–1.0 mg ⁄L, and resistant
‡ 2 mg ⁄L; (2) ﬂucytosine, susceptible £ 4 mg ⁄L, intermediate
8–16 mg ⁄L, and resistant ‡ 32 mg ⁄L; (3) ﬂuconazole, suscept-
ible £ 2 mg ⁄L, intermediate 4–8 mg ⁄L, and resistant
‡ 16 mg ⁄L; (4) itraconazole, susceptible £ 0.12 mg ⁄L, interme-
diate 0.25–0.50 mg ⁄L, and resistant ‡ 1 mg ⁄L; (5) voriconazole,
susceptible £ 0.25 mg ⁄L, intermediate 0.50–1.0 mg ⁄L, and
resistant ‡ 2 mg ⁄L; and (6) ketoconazole, susceptible
£ 0.12 mg ⁄L, intermediate 0.25–0.50 mg ⁄L, and resistant
‡ 1 mg ⁄L. Similar interpretative breakpoints were used to
classify Sensititre YeastOne. Interpretative criteria for Etest,
Fungitest and Neo-Sensitabs were according to the manufac-
turers’ recommendations.
Categorical agreement was deﬁned as the percentage of
isolates classiﬁed in the same category with the reference
procedure and each commercial technique. Discrepancies were
considered to be very major if an isolate classiﬁed as resistant
by the reference method was categorised as susceptible by the
commercial method. Discrepancies were considered to be
major if an isolate classiﬁed as susceptible by the reference
method was classiﬁed as resistant by the commercial tech-
nique. Errors were classiﬁed as minor when susceptible vs.
intermediate, resistant vs. intermediate, intermediate vs. sus-
ceptible or intermediate vs. resistant discrepancies were
observed [7].
All statistical analyses were performed with SPSS v. 12.0
software (SPSS, Madrid, Spain).
RESULTS
Susceptibility results obtained by the EUCAST
procedure are shown in Table 1. Broad MIC
ranges of each antifungal agent were observed.
Four isolates (one Candida albicans and three
Candida tropicalis) exhibited resistance in vitro to
amphotericin B. Eleven isolates (four C. albicans
and seven C. krusei) had ﬂucytosine MICs that
were categorised as intermediate or resistant. In
total, 39 isolates (ten C. albicans, 11 C. tropicalis,
two C. parapsilosis, two Candida glabrata, ten
C. krusei, one Candida lusitaniae and three Candida
guilliermondii) had ﬂuconazole MICs ‡ 16 mg ⁄L.
In-vitro resistance to itraconazole was observed
for 11 isolates (ﬁve C. albicans, ﬁve C. tropicalis and
one C. guilliermondii). Ten isolates (three C. albi-
cans, six C. tropicalis and one C. guilliermondii) had
voriconazole MICs > 1 mg ⁄L. Finally, 18 isolates
(four C. albicans, four C. tropicalis, two C. glabrata,
six C. krusei, one C. lusitaniae and one C. guillier-
mondii) had resistance to ketoconazole.
Table 2 shows the MIC ranges and susceptibil-
ity data obtained for the quality control strains by
each susceptibility testing method. Tables 3 and 4
show the correlation indices (ICCs, r and gamma)
between the EUCAST results and the susceptibil-
ity results obtained with each commercial tech-
nique, grouped according to each species of
Candida and each antifungal agent, respectively.
Overall, the agreement between the EUCAST and
Sensititre YeastOne data was 75%, with an ICC
value of 0.92 (p < 0.01). The agreement between
the EUCAST and Etest data was 90.4%, with an
ICC value of 0.89 (p < 0.01). Pearson’s coefﬁcient
for EUCAST and Neo-Sensitabs data was ) 0.90
(p < 0.01), indicating that the higher MIC values
with the EUCAST procedure were associated
with smaller inhibition diameters. The gamma
probabilistic measure between reference method
and Fungitest data was 0.95 (p < 0.01). The lowest
percentages of agreement and correlation indices
were observed with data collected by Sensititre
YeastOne. Notably, agreement for amphotericin B
MICs was 50.5%, with an ICC value of 0.29 (no
statistical signiﬁcance).
Regarding categorical agreement, Table 5 shows
the very major, major and minor discrepancies
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observed between the EUCAST and commercial
techniques, grouped according to antifungal agent.
Very major errors were found infrequently, but
some discrepancies should be highlighted. In total,
33% of susceptibility values obtained by Sensititre
YeastOne were categorised incorrectly when
Table 3. Agreement values and cor-
relation coefﬁcients between EU-
CAST and commercial technique
data, grouped according to Candida
spp.
Species




Gamma measureAgreement (%) ICC Agreement (%) ICC
C. albicans 90.0 0.91b 92.5 0.86b ) 0.93b 0.96b
C. tropicalis 56.1 0.69b 88.2 0.81b ) 0.91b 0.94b
C. parapsilosis 88.2 0.88b 91.2 0.80b ) 0.92b 0.95b
C. glabrata 69.1 0.76b 87.5 0.76b ) 0.89b 0.88b
C. krusei 74.0 0.88b 91.4 0.88b ) 0.90b 0.88b
C. lusitaniae 72.9 0.81b 86.8 0.74b ) 0.91b 0.95b
C. guilliermondii 75.0 0.85b 89.4 0.82b ) 0.92b 0.96b
ICC, intraclass correlation coefﬁcient.
aPearson’s coefﬁcient between EUCAST MIC values and inhibition diameters in cm.
bp < 0.01.
Table 4. Agreement values and cor-
relation coefﬁcients between EU-
CAST and commercial technique







Gamma measureAgreement (%) ICC Agreement (%) ICC
Amphotericin B 50.5 0.29 87.1 0.83b ) 0.89b 0.94b
Flucytosine 72.0 0.81b 88.9 0.84b ) 0.90b 0.95b
Fluconazole 90.0 0.93b 91.0 0.95b ) 0.93b 0.95b
Itraconazole 81.0 0.85b 90.0 0.80b ) 0.88b 0.93b
Voriconazole ND ND 92.0 0.93b ND ND
Ketoconazole 82.0 0.91b 91.0 0.94b ) 0.89b 0.86b
ICC, intraclass correlation coefﬁcient; ND, not done.
aPearson’s coefﬁcient between EUCAST MIC values and inhibition diameters in cm.
bp < 0.01.
Table 2. MIC ranges and susceptibility data (30 repetitions on different days) for quality control strains grouped according
to susceptibility testing method
Quality control strain Methoda Amphotericin B Flucytosine Fluconazole Itraconazole Voriconazole Ketoconazole
C. krusei
ATCC 6258
EUCAST 0.12–0.50 1.0–4.0 8.0–32.0 0.06–0.25 0.06–0.25 0.06–0.25
YeastOne 0.50–2.0 4.0–8.0 8.0–64.0 0.12–0.50 ND 0.12–0.50
Etest 0.50–1.0 8.0–32.0 32.0–256.0 0.12–0.50 0.12–0.50 0.12–0.50
Neo-Sensitabs 21.0–23.2 14.2–18.8 11.8–18.8 22.5–24.1 ND 23.1–30.4
Fungitestb < 2.0 2.0–32.0 8.0–64.0 < 0.50 ND < 0.50–4.0
C. parapsilosis
ATCC 22019
EUCAST 0.12–0.50 0.12–0.50 1.0–4.0 0.03–0.12 0.01–0.06 0.01–0.06
YeastOne 0.25–1.0 0.06–0.25 0.50–4.0 0.12–0.50 ND 0.03.0.12
Etest 0.25–1.0 0.12–0.50 2.0–8.0 0.06–0.12 0.03–0.12 0.03–0.12
Neo-Sensitabs 23.1–25.6 40.5–47.8 34.7–38.6 20.5–24.2 ND 35.5–40.6
Fungitestb < 2.0 < 2.0 < 8.0 < 0.50 ND < 0.50
ND, Not done.
aEUCAST, YeastOne, Etest and Fungitest values are in mg ⁄L, while Neo-Sensitabs data are inhibition diameters in mm.
bFungitest susceptibility data are expressed according to the two different concentrations of antifungal agents that are included in the commercial kit.
Table 5. Categorical agreement between EUCAST and commercial technique data, grouped according to type of
discrepancy (very major, major and minor errors) and antifungal agent
Antifungal agent
Number and percentage of discrepanciesa
Sensititre YeastOne Etest Neo-Sensitabs Fungitest
Very major Major Minor Very major Major Minor Very major Major Minor Very major Major Minor
Amphotericin B 0 37 (13%) 216 (78%) 0 0 9 (3.2%) 0 0 4 (1.4%) 0 0 18 (6.5%)
Flucytosine 0 0 18 (6.5%) 0 9 (3.2%) 27 (7.5%) 0 14 (5.0%) 28 (10%) 0 0 9 (3.2%)
Fluconazole 0 0 32 (11.5%) 0 0 3 (1.1%) 15 (5.4%) 0 32 (11.5%) 0 0 64 (23%)
Itraconazole 0 0 92 (33%) 0 9 (3.2%) 46 (16.5%) 3 (1.1%) 0 63 (22.5%) 0 0 19 (7%)
Voriconazole ND ND ND 0 0 10 (3.6%) ND ND ND ND ND ND
Ketoconazole 0 0 65 (23.5%) 0 0 46 (16.5%) 3 (1.1%) 0 37 (13%) 0 0 46 (16.5%)
ND, not done. Very major discrepancies are marked in bold type.
aCalculated following three repetitions on different days (3 · 93 isolates = 279 values for each antifungal agent).
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compared with the EUCAST results. The MICs
obtained with the commercial technique were
consistently higher (two or three two-fold dilu-
tions) than those obtained with the EUCAST
method. Very major errors were not observed, but
37 (2.6%) of 1395 determinations were classiﬁed
as major errors, with 423 (30.3%) minor errors.
The highest discrepancy was obtained for amph-
otericin B, with 253 (91%) of 279 MIC values
misclassiﬁed, including 37 major and 216 minor
discrepancies. Eight isolates (four C. krusei, three
C. tropicalis and one C. glabrata), categorised as
amphotericin B-susceptible by the EUCAST meth-
od, were classiﬁed as resistant in vitro by Sensi-
titre YeastOne. It should be noted that agreement
and correlation were particularly signiﬁcant for
C. albicans (90% and 0.91; Table 3). For other
species, the agreement was < 89% and the ICC
value was £ 0.88 (p < 0.01).
Minor discrepancies were noted for 141
(8.4%) of 1674 Etest results, compared with the
EUCAST reference method. The highest rates of
disagreement were observed for itraconazole
and ketoconazole MICs, particularly for isolates
of C. krusei and C. glabrata, with c. 17% of results
being at variance with reference values. Major
errors were found rarely (18 (1.1%) of 1674
determinations), and resulted from the classiﬁ-
cation of some itraconazole-susceptible C. krusei
isolates as resistant. Very major errors were not
observed.
Very major errors were observed between the
EUCAST and Neo-Sensitabs results. Five isolates
(two C. albicans, two C. glabrata and one
C. tropicalis), classiﬁed as ﬂuconazole-resistant
with the EUCAST method, were susceptible with
the Neo-Sensitabs technique, and one C. tropicalis
isolate, resistant to itraconazole and ketoconazole,
was classiﬁed as susceptible to both agentswith the
commercial method. Very major errors were noted
consistently after three repetitions. In addition, 14
(1%) of 1395 determinations were considered to be
major errors, and 168 (11.7%) were minor errors.
Finally, neither very major errors nor major
discrepancies were observed for the EUCAST and
Fungitest results. Minor discrepancies were noted
in 156 (11.2%) of 1395 MIC determinations,
particularly for C. krusei and C. glabrata isolates,
where 25% of isolates classiﬁed as resistant to
ﬂuconazole and ketoconazole with the EUCAST
method were misclassiﬁed as intermediate with
the commercial technique.
DISCUSSION
Commercial techniques have some advantages
over reference methods. Generally, they are easier
to perform, are more economical and can be used
readily in clinical laboratories. However, some
commercial techniques are not signiﬁcantly less
expensive than microdilution reference proce-
dures, and can provide susceptibility results for
amphotericin B and azole agents that are in total
disagreement with those obtained with reference
methods.
The present study evaluated the concordance
between the EUCAST reference method and four
commercial techniques, as well as the ability of
the four commercial techniques to detect clinical
isolates resistant in vitro to either amphotericin B
or azole agents. Overall, the agreement and
correlation with the EUCAST data were high,
with correlation indices of 0.92 for Sensititre
YeastOne, 0.89 for Etest, ) 0.90 for Neo-Sensitabs,
and 0.95 for Fungitest (p < 0.01). However, the
Sensititre YeastOne and EUCAST data were not
comparable for amphotericin B, with 91% of
susceptibility results obtained by the commercial
technique being misclassiﬁed. Very major errors
were not found, but most isolates susceptible to
amphotericin B in vitro were categorised as
intermediate with Sensititre YeastOne (216 of
279 determinations), with MICs obtained by the
commercial method being two or three two-fold
concentrations higher than EUCAST MICs. Sim-
ilar differences have been reported between Sen-
sititre YeastOne and NCCLS reference procedures
[6,10,14], indicating that the commercial method
could be unreliable for amphotericin B suscepti-
bility testing. However, as reported previously
[6,7,10,14,18], Sensititre YeastOne had a high
percentage agreement and correlation index for
ﬂuconazole MICs.
Etest results generally matched EUCAST MIC
values. Etest detected isolates resistant to amph-
otericin B and ﬂuconazole, with no very major
errors. The commercial method identiﬁed amph-
otericin B-resistant isolates accurately, as found
previously in comparisons between the NCCLS
and Etest methods [21,35,36], although the limited
number of amphotericin B-resistant isolates inclu-
ded in the present study precludes further ana-
lysis. The lowest percentages of agreement were
observed for MICs of azole agents, and for some
isolates of C. tropicalis, C. glabrata, C. krusei and
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C. lusitaniae. These isolates often required incuba-
tion for 48 h, and were all subject to signiﬁcant
trailing growth, such that the MICs at 24 h were
much lower than at 48 h. It could be argued that
trailing growth may be an important source of
variability and inaccuracy in MIC determination
with Etest [22], but, in general, Etest appeared to
be a convenient alternative method for testing the
susceptibility of Candida spp. [5,11,13,16,17].
The only commercial technique tested that
exhibited very major errors was the Neo-Sensitabs
agar diffusion method, with 5.4% of isolates
classiﬁed as resistant by the EUCAST procedure
being misclassiﬁed as susceptible. A similar
observation was made in studies that compared
the NCCLS and Neo-Sensitabs methods [19,20].
These data indicate that this commercial method
is not a reliable procedure for the identiﬁcation of
ﬂuconazole-resistant isolates.
Fungitest and EUCAST susceptibility determi-
nations were comparable for the ﬁve antifungal
agents tested. In contrast to the other commercial
methods, Fungitest does not provide MIC values,
but is a colorimetric breakpoint method. Several
studies have reported very major discrepancies
(0.6–16.6%) between the NCCLS and Fungitest
methods for ﬂuconazole susceptibility testing
[8,12,20,23,24]. However, the present study did
not reveal any very major errors, and only 11.2%
minor errors were detected, in agreement with a
previous study that recommended Fungitest as a
simple screening procedure for susceptibility
testing of Candida [12].
In conclusion, susceptibility testing results
obtained by the Sensititre YeastOne, Etest, Neo-
Sensitabs and Fungitest methods were generally
comparable to those obtained by the EUCAST
procedure, with statistically signiﬁcant correla-
tion indices. However, amphotericin B MICs
obtained by Sensititre YeastOne were consistently
higher and, although very major errors were not
observed, 91% of MICs were misclassiﬁed. Iso-
lates resistant to amphotericin B and ﬂuconazole
were identiﬁed correctly by Sensititre YeastOne,
Etest and Fungitest. Neo-Sensitabs identiﬁed
amphotericin B-resistant isolates, but misclassi-
ﬁed > 5% of ﬂuconazole-resistant isolates as
susceptible. These commercial methods, partic-
ularly Etest and Fungitest, appear to be suitable
alternatives to the EUCAST procedure for anti-
fungal susceptibility testing of clinical isolates of
Candida.
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